Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

2007

Revenues $ -- $ -- $ -- $ --

Expenses:

Research and

development 2,148,839 1,247,601 8,503,110 5,543,175

General and

administrative 765,112 1,248,385 5,797,355 4,092,990

Total expenses 2,913,951 2,495,986 14,300,465 9,636,165

Loss from

operations (2,913,951) (2,495,986) (14,300,465) (9,636,165)

Interest income, net 32,838 66,586 223,984 370,554

State tax benefit -- -- 1,755,380 510,467

Net loss $(2,881,113) $(2,429,400) $(12,321,101) $(8,755,144)

Net loss per

share - basic

and diluted $ (0.06) $ (0.05) $ (0.26) $ (0.19)

Shares used in

computation of net

loss per share:

Basic and

diluted 47,266,000 45,489,000 46,919,000 44,958,000

Balance Sheet Data:

July 31, July 31,

2008 2007

Cash and cash equivalents $ 4,661,656 $ 6,968,172

Total assets $ 5,320,036 $ 7,820,499

Current liabilities $ 2,882,034 $ 1,829,900

Accumulated deficit $(104,392,856) $(92,071,755)

Total stockholders' equity (deficiency) $ (3,556,606) $ 5,778,480

Media and Investor Contact:
David Schull or Wendy Lau

Russo Partners

212-845-4271

David.Schull@russopartnersllc.com

Wendy.Lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Mapp Biopharmaceutical,s valiant effort to produce ... fight the Ebola outbreak will make the public ... of pharmaceuticals can be, according to Kalorama Information.  ... some may be taken aback by the three-month ... knowledge are well aware of the complex issues ...
(Date:10/20/2014)... Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... brings Q3 orders to $5.8 million and provides a good start ... North America and one in the ... new projects at record levels," said Peter Bruijns , President ... the end of Q3 than they have been for any complete ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/20/2014)... 2014 Local veterinary surgeon, Dr. Tim ... study of donor stem cells for dogs with osteoarthritis. ... and has performed clinical stem cell therapy for 7 ... determine if a single injection of donor stem cells ... reduce pain and inflammation in the treated joints. ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Oct. 30 Cephalon, Inc. (Nasdaq:,CEPH) today announced that ... held on,November 5, 2008, will be webcast live on ... ., Cephalon,s senior management will review the company,s ... will be delivered on Wednesday, November 5, 2008 beginning ...
... - Cytochroma today announced the,appointment of Ulrik Spork to ... on the Company,s Board and replaces Dr. Soren Schifter,who ... remains unchanged at,six members., "We are very pleased ... to drawing on his expertise and experiences as we ...
... Discuss Continued Expansion of DXL(TM) Patent Protection at ... 7th Annual BIO ... InNexus,Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;, http://www.ixsbio.com ... antibodies based on its Dynamic Cross Linking,(DXL(TM)) technology, announced today ...
Cached Biology Technology:Cephalon, Inc. to Webcast Analyst Day 2Cephalon, Inc. to Webcast Analyst Day 3InNexus Biotechnology Receives Patent Grants in Europe 2
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2
... The Translational Genomics Research Institute (TGen) provides Arizona with ... to the results of an independent analysis released today. ... TGen-led research, a study by the research firm Tripp ... to $321.3 million by 2025. "As we make ...
... September 28, 2009 -- Soybeans contain high ... have antioxidant properties. These molecules can be used ... specific health-beneficial properties and can be used in ... in four forms (α, β, γ, and δ) ...
... biology continue to develop as two of the most ... that the public is almost completely unaware of the ... American adults conducted by Peter D. Hart Research Associates ... 90 percent of Americans think the public should be ...
Cached Biology News:TGen provides Arizona with $77 million in annual economic impact 2TGen provides Arizona with $77 million in annual economic impact 3Eat soybeans to prevent diseases 2Nanotechnology and synthetic biology: What does the American public think? 2
... is an integrated digital microscope and camera ... equipment setup, optical adjustment or software installation. ... technology, COOLSCOPE combines simplicity and advanced technology ... offers simultaneous viewing of a macro image ...
... microscope is described by end-users to be ... the fundamentals of light microscopy and electronic ... footprint, it does not require much space ... busy lab environment. The DM-BA300 combines Motic's ...
... The TUNEL-based assay kit provides complete ... cells for convenient detection of DNA ... sections. The incorporation of BrdU in ... biotinylated or digoxigenylated methods. Results can ...
... ergonomic microscopes are now available in digital ... DM-BA200 comes packed with Motic's patented Colour ... plug and play digital image capture head. ... a reversed quadruple nosepiece, deliver high quality ...
Biology Products: